Corporate Breaking News
Corporate Breaking News
Home : Isofol Reports Early Tumor Shrinkage in Patients With Colorectal Cancer in Phase 1/2a Open Label Extension Study with Arfolitixorin
Jan 17
2019

Isofol Reports Early Tumor Shrinkage in Patients With Colorectal Cancer in Phase 1/2a Open Label Extension Study with Arfolitixorin

GOTHENBURG, Sweden, Jan. 17, 2019 /PRNewswire/ -- Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced positive results from an open-label extension study for the ISO-CC-005 Phase 1/2a study of arfolitixorin in patients with metastatic colorectal cancer (mCRC)....
Source:https://www.prnewswire.com:443/news-releases/isofol-reports-early-tumor-shrinkage-in-patients-with-colorectal-cancer-in-phase-12a-open-label-extension-study-with-arfolitixorin-300780071.html
 
Related News
» Returns Solution ZigZag Global Receives Multi-Million GBP Investment
» Online Nominations are now Open for Hozpitality Group's Middle East Chef Excellence Awards to be Held at Rixos Premium Dubai on 12th June 2019
Home
About us
Archive
Sitemap
Powered By Corporate Breaking News.com Home| About us| Archive News| Sitemap